Sept 29 (Reuters) - Genfit SA GNFT.PA
* REPORTED ON WEDNESDAY FIRST HALF-YEAR 2022 FINANCIAL
RESULTS
* AS OF JUNE 30, 2022, CASH AND CASH EQUIVALENTS TOTALED EUR
209
MILLION
* H1 2022 NET LOSS TOTALED EUR 10 MLN VS NET PROFIT OF EUR 9
MLN
IN 2021
* H1 2022 OPERATING INCOME AMOUNTED TO EUR 12 MLN VS EUR 3
MLN IN
2021
* H1 2022 OPERATING EXPENSES AMOUNTED TO EUR 27 MLN VS EUR
33 MLN
IN 2021
* H1 2022 FINANCIAL INCOME WAS A GAIN OF EUR 4 MLN VS GAIN
OF OF
EUR 36 MLN IN 2021
* OUTLOOK: WITH VERSANTIS ACQUISITION TO BE COMPLETED
SHORTLY,
GROUP WILL HAVE SIX ONGOING PROGRAMS AT ALL STAGES OF
DEVELOPMENT IN FIVE DIFFERENT INDICATIONS
* OUTLOOK: THE SIX PROGRAMS SHOULD PROVIDE STEADY STREAM OF
NEWS
OVER NEXT FEW MONTHS, YEARS, WITH IMPORTANT CLINICAL DATA IN
RELATIVELY SHORT TERM
* OUTLOOK: PHASE 3 PBC CLINICAL DATA READ OUT EXPECTED IN Q2
2023
Source text : https://bit.ly/3rg972F
Further company coverage: GNFT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;))